

# Andrei Goga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1977249/publications.pdf>

Version: 2024-02-01

67  
papers

9,106  
citations

66343

42  
h-index

102487

66  
g-index

74  
all docs

74  
docs citations

74  
times ranked

17546  
citing authors

#	ARTICLE	IF	CITATIONS
1	NCI's publication affiliation conundrum: Reframing innovation to incentivize an equitable path for advocate representation. <i>Translational Oncology</i> , 2022, 16, 101325.	3.7	0
2	Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability. <i>Nature Chemical Biology</i> , 2022, 18, 751-761.	8.0	47
3	Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	21
4	Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice. <i>JCO Precision Oncology</i> , 2022, , .	3.0	4
5	MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 122-134.	3.7	109
6	In Vivo Optical Metabolic Imaging of Long-Chain Fatty Acid Uptake in Orthotopic Models of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 148.	3.7	16
7	Oncogene-regulated release of extracellular vesicles. <i>Developmental Cell</i> , 2021, 56, 1989-2006.e6.	7.0	37
8	Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. <i>Npj Breast Cancer</i> , 2021, 7, 113.	5.2	10
9	MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. <i>Cell Reports</i> , 2020, 30, 3368-3382.e7.	6.4	44
10	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. <i>Cell</i> , 2019, 177, 231-242.	28.9	152
11	Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. <i>Nature Medicine</i> , 2019, 25, 111-118.	30.7	196
12	New Horizons in Advocacy Engaged Physical Sciences and Oncology Research. <i>Trends in Cancer</i> , 2018, 4, 260-264.	7.4	6
13	Cancer cells exploit an orphan RNA to drive metastatic progression. <i>Nature Medicine</i> , 2018, 24, 1743-1751.	30.7	26
14	microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis. <i>Gastroenterology</i> , 2018, 155, 1951-1966.e26.	1.3	86
15	Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity. <i>Nature Communications</i> , 2018, 9, 2028.	12.8	256
16	Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. <i>Nature Chemical Biology</i> , 2018, 14, 768-777.	8.0	64
17	Development of high resolution 3D hyperpolarized carbon-13 MR molecular imaging techniques. <i>Magnetic Resonance Imaging</i> , 2017, 38, 152-162.	1.8	20
18	<sc>MYC</sc>-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer. <i>EMBO Reports</i> , 2017, 18, 569-585.	4.5	55

#	ARTICLE	IF	CITATIONS
19	Diverse regulation of mammary epithelial growth and branching morphogenesis through noncanonical Wnt signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3121-3126.	7.1	55
20	Comprehensive analysis of normal adjacent to tumor transcriptomes. <i>Nature Communications</i> , 2017, 8, 1077.	12.8	394
21	Cancer recurrence monitoring using hyperpolarized [1-13C]pyruvate metabolic imaging in murine breast cancer model. <i>Magnetic Resonance Imaging</i> , 2017, 43, 105-109.	1.8	13
22	In vivo Reprogramming of Cancer Metabolism by MYC. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 35.	3.7	48
23	Protein Sialylation Regulates a Gene Expression Signature that Promotes Breast Cancer Cell Pathogenicity. <i>ACS Chemical Biology</i> , 2016, 11, 2131-2139.	3.4	43
24	GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity. <i>Cell Chemical Biology</i> , 2016, 23, 567-578.	5.2	122
25	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. <i>Nature Medicine</i> , 2016, 22, 1321-1329.	30.7	138
26	Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. <i>Nature Medicine</i> , 2016, 22, 427-432.	30.7	381
27	Biogenesis, delivery, and function of extracellular RNA. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 27494.	12.2	80
28	CDK1 Inhibition Targets the p53-NOXA-MCL1 Axis, Selectively Kills Embryonic Stem Cells, and Prevents Teratoma Formation. <i>Stem Cell Reports</i> , 2015, 4, 374-389.	4.8	59
29	Identification of Chemical Inhibitors of $\beta$ -Catenin-Driven Liver Tumorigenesis in Zebrafish. <i>PLoS Genetics</i> , 2015, 11, e1005305.	3.5	67
30	Pan-viral-microRNA screening identifies interferon inhibition as a common function of diverse viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1856-1861.	7.1	9
31	Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PFAH1B2 and 1B3 in Cancer. <i>ACS Chemical Biology</i> , 2015, 10, 1624-1630.	3.4	43
32	Direct and indirect targeting of MYC to treat acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 35-46.	2.3	31
33	Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. <i>Nature</i> , 2015, 526, 131-135.	27.8	767
34	Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors. <i>Human Molecular Genetics</i> , 2015, 24, 7421-7431.	2.9	24
35	Fas-Activated Mitochondrial Apoptosis Culls Stalled Embryonic Stem Cells to Promote Differentiation. <i>Current Biology</i> , 2015, 25, 3110-3118.	3.9	16
36	Linking Tumor Mutations to Drug Responses via a Quantitative Chemical-Genetic Interaction Map. <i>Cancer Discovery</i> , 2015, 5, 154-167.	9.4	57

#	ARTICLE	IF	CITATIONS
37	Taking on Challenging Targets: Making MYC Druggable. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e497-e502.	3.8	49
38	MicroRNA-494 within an oncogenic microRNA megacluster regulates G <sub>1</sub> /S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology, 2014, 59, 202-215.	7.3	109
39	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. Cancer Discovery, 2014, 4, 232-245.	9.4	413
40	Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1472-1479.	1.6	31
41	Inositol Phosphate Recycling Regulates Glycolytic and Lipid Metabolism That Drives Cancer Aggressiveness. ACS Chemical Biology, 2014, 9, 1340-1350.	3.4	39
42	Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood, 2014, 124, 2081-2090.	1.4	72
43	Quantitative measurement of cancer metabolism using stimulated echo hyperpolarized carbon-13 MRS. Magnetic Resonance in Medicine, 2014, 71, 1-11.	3.0	27
44	Endogenous Nuclear RNAi Mediates Behavioral Adaptation to Odor. Cell, 2013, 154, 1010-1022.	28.9	74
45	A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. ELife, 2013, 2, e00822.	6.0	75
46	Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1019-27.	7.1	64
47	MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. Journal of Experimental Medicine, 2012, 209, 679-696.	8.5	309
48	Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12722-12727.	7.1	34
49	IRE1 $\alpha$ Cleaves Select microRNAs During ER Stress to Derepress Translation of Proapoptotic Caspase-2. Science, 2012, 338, 818-822.	12.6	550
50	Investigating tumor perfusion and metabolism using multiple hyperpolarized <sup>13</sup> C compounds: HP001, pyruvate and urea. Magnetic Resonance Imaging, 2012, 30, 305-311.	1.8	69
51	<sup>13</sup> C-Pyruvate Imaging Reveals Alterations in Glycolysis that Precede c-Myc-Induced Tumor Formation and Regression. Cell Metabolism, 2011, 14, 131-142.	16.2	210
52	Switching Cdk2 On or Off with Small Molecules to Reveal Requirements in Human Cell Proliferation. Molecular Cell, 2011, 42, 624-636.	9.7	76
53	Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment. Science Translational Medicine, 2011, 3, 73ra21.	12.4	484
54	Imaging of blood flow using hyperpolarized [ <sup>13</sup> C]Urea in preclinical cancer models. Journal of Magnetic Resonance Imaging, 2011, 33, 692-697.	3.4	105

#	ARTICLE	IF	CITATIONS
55	3D compressed sensing for highly accelerated hyperpolarized <sup>13</sup> C MRSI with in vivo applications to transgenic mouse models of cancer. <i>Magnetic Resonance in Medicine</i> , 2010, 63, 312-321.	3.0	126
56	miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. <i>Nature Medicine</i> , 2010, 16, 1134-1140.	30.7	180
57	Therapeutic potential of a synthetic lethal interaction between the <i>MYC</i> proto-oncogene and inhibition of aurora-B kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13836-13841.	7.1	157
58	Nuclear entry of a cGMP-dependent kinase converts transient into long-lasting olfactory adaptation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 6016-6021.	7.1	50
59	Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. <i>Blood</i> , 2010, 116, 1498-1505.	1.4	196
60	Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion. <i>Journal of Biological Chemistry</i> , 2009, 284, 18515-18524.	3.4	176
61	A 3'UTR Pumilio-Binding Element Directs Translational Activation in Olfactory Sensory Neurons. <i>Neuron</i> , 2009, 61, 57-70.	8.1	103
62	Hepatic Stem-like Phenotype and Interplay of Wnt/ $\beta$ 2-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer. <i>Cancer Cell</i> , 2008, 14, 471-484.	16.8	443
63	Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b. <i>Journal of Biological Chemistry</i> , 2007, 282, 1479-1486.	3.4	551
64	Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. <i>Nature Medicine</i> , 2007, 13, 820-827.	30.7	283
65	Anti-Oncomir Suppression of Tumor Phenotypes. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2007, 7, 199-202.	3.4	17
66	Short RNA duplexes produced by hydrolysis with <i>Escherichia coli</i> RNase III mediate effective RNA interference in mammalian cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 9942-9947.	7.1	285
67	Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. <i>Cell</i> , 1995, 82, 981-988.	28.9	249